Pharmacokinetic interactions of the microsomal triglyceride transfer protein inhibitor, lomitapide, with drugs commonly used in the management of hypercholesterolemia

Pharmacotherapy

Volumn 34, Issue 3, 2014, Pages 227-239

  Tuteja, Sony ^a   Duffy, Danielle ^b   Dunbar, Richard L ^a   Movva, Rajesh ^a   Gadi, Ram ^a   Bloedon, Leanne T ^c   Cuchel, Marina ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c Aegerion Pharmaceuticals   (United States)

Author keywords

CYP3A4; Drug interaction; Lomitapide; Statins

Indexed keywords

ATORVASTATIN; CYTOCHROME P450 3A4; EZETIMIBE; FENOFIBRATE; LOMITAPIDE; NICOTINIC ACID; ROSUVASTATIN; SIMVASTATIN;

ABDOMINAL PAIN; ADULT; ANXIETY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG SCREENING; DRUG WITHDRAWAL; FEMALE; FLUSHING; HUMAN; HUMAN EXPERIMENT; HYPERCHOLESTEROLEMIA; LIVER FUNCTION TEST; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NAUSEA; NORMAL HUMAN; PRURITUS; RASH; SIDE EFFECT; SINGLE DRUG DOSE; STOMACH DISCOMFORT;

ADOLESCENT; ADULT; AGED; ANTICHOLESTEREMIC AGENTS; BENZIMIDAZOLES; CARRIER PROTEINS; DISEASE MANAGEMENT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84895538888     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1351     Document Type: Article

References (30)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285: 2486-97.
2. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110: 227-39. (Pubitemid 38924592)
3. Lomitapide (Juxtapid) U.S. prescribing information. Aegerion Pharmaceuticals, Cambridge, MA, 2012.
4. Burnett JR, Watts GF. MTP inhibition as a treatment for dyslipidaemias: time to deliver or empty promises? Expert Opin Ther Targets 2007;11: 181-9. (Pubitemid 46188813)
5. Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 2007;356: 148-56. (Pubitemid 46089675)
6. Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013;381 (9860): 40-6.
7. Samaha FF, McKenney J, Bloedon LT, Sasiela WJ, Rader DJ. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat Clin Pract Cardiovasc Med 2008;5: 497-505.
8. Aegerion Pharmaceuticals Inc. Data on file. Cambridge, MA; 2008.
9. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006;80: 565-81. (Pubitemid 44908269)
10. Martin PD, Warwick MJ, Dane AL, et al. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther 2003;25: 2822-35. (Pubitemid 37510592)
11. Schneck DW, Birmingham BK, Zalikowski JA, et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 2004;75: 455-63. (Pubitemid 38534566)
12. Patrick JE, Kosoglou T, Stauber KL, et al. Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects. Drug Metab Dispos 2002;30: 430-7. (Pubitemid 34263828)
13. Gustavson LE, Schweitzer SM, Burt DA, et al. Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: a phase I, open-label, multiple-dose, three-period crossover study in healthy subjects. Clin Ther 2006;28: 373-87. (Pubitemid 43783438)
14. Carlson LA, Hanngren A. Initial distribution in mice of 3 h-labeled nicotinic acid studied with autoradiography. Life Sci 1964;3: 867-71.
15. Ding RW, Kolbe K, Merz B, de Vries J, Weber E, Benet LZ. Pharmacokinetics of nicotinic acid-salicylic acid interaction. Clin Pharmacol Ther 1989;46: 642-7. (Pubitemid 20031846)
16. Mrochek JE, Jolley RL, Young DS, Turner WJ. Metabolic response of humans to ingestion of nicotinic acid and nicotinamide. Clin Chem 1976;22: 1821-7.
17. Lennernas H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 2003;42: 1141-60. (Pubitemid 37357650)
18. U.S. Department of Health and Human Services Food and Drug Administration. Guidance for industry drug interaction studies-study design, data analysis, and implications for dosing and labeling. Draft Guidance, February 2006.
19. Aegerion Pharmaceuticals Inc. Data on file. Cambridge, MA; 2011.
20. Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 2004;94: 1140-6. (Pubitemid 39424216)
21. Kantola T, Kivisto KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 1998;64: 58-65. (Pubitemid 28377331)
22. Fujino H, Saito T, Tsunenari Y, Kojima J, Sakaeda T. Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors. Xenobiotica 2004;34: 961-71. (Pubitemid 40070099)
23. Aegerion Pharmaceuticals Inc. Data on file. Cambridge, MA; 2012.
24. Keskitalo JE, Kurkinen KJ, Neuvoneni PJ, Niemi M. ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clin Pharmacol Ther 2008;84: 457-61.
25. Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2009;86: 197-203.
26. Menon RM, Adams MH, Gonzalez MA, Tolbert DS, Leu JH, Cefali EA. Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation. Int J Clin Pharmacol Ther 2007;45: 448-54. (Pubitemid 47243941)
27. Kosoglou T, Zhu Y, Statkevich P, et al. Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects. Eur J Clin Pharmacol 2011;67: 483-92.
28. Narwal R, Akhlaghi F, Asberg A, Hermann M, Rosenbaum SE. Development of a population pharmacokinetic model for atorvastatin acid and its lactone metabolite. Clin Pharmacokinet 2010;49: 693-702.
29. Chung E, Nafziger AN, Kazierad DJ, Bertino JS Jr. Comparison of midazolam and simvastatin as cytochrome P450 3A probes. Clin Pharmacol Ther 2006;79: 350-61.
30. Wetterau JR, Lin MC, Jamil H. Microsomal triglyceride transfer protein. Biochim Biophys Acta 1997;1345: 136-50. (Pubitemid 27138415)